Navigation Links
AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Date:12/7/2009

ward to the initiation of the Phase 3 study in this same indication, this month", stated Juergen Engel, Ph.D., President and CEO at AEterna Zentaris.

Keryx has been granted a Special Protocol Assessment (SPA) from the FDA for the upcoming Phase 3 study of perifosine in multiple myeloma. Additionally, the FDA has granted perifosine Orphan Drug and Fast Track designations in this indication.

About Perifosine (KRX-0401)

Perifosine is a novel oral anticancer agent that modulates several key signal transduction pathways, including Akt, MAPK, and JNK that have been shown to be critical for the survival of cancer cells. Perifosine has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. Perifosine is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Perifosine has also received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.

About Multiple Myeloma

Multiple myeloma, a cancer of the plasma cell, is an incurable but treatable disease. Multiple myeloma is the second most-common hematologic cancer, representing 1% of all cancer diagnoses and 2% of all cancer deaths. According to the American Cancer Society, in 2009 there will be an estimated 20,580 new cases of multiple myeloma and an estimated 10,500 deaths from multiple myeloma in the United States. To date, several FDA approved therapies exist for the treatment of multiple myeloma. Despite this progress, patients continue to relapse, become refractory to prior treatments and eventually die from their disease. Thus, new therapies are needed to treat these patients and extend their survival.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical compa
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... The Conference Forum announced ... Advance Clinical Trials conference taking place on September 19-20 ... , Disruptive thinkers from Novartis, Pfizer, Eli Lilly, ... approaches to reduce expensive infrastructure, engage patients and generate ... be big, or novel, or it must change the ...
(Date:5/22/2013)... Genedata, a leading provider of ... and life science research, today announced AB Enzymes ... its bioinformatics platform for strain genome data management ... AB Enzymes, one of the world’s oldest and ... Genedata Selector accompanied by bioinformatics consulting services. Genedata ...
(Date:5/22/2013)... Alton Housing Authority was hit by bed bugs. ... that their presence has already caused the company $35,000 for ... big spending, My Cleaning Products shared a way how ... in the report that to clear the infestation , ... its employees also attended a mandatory training on bed bugs, ...
(Date:5/21/2013)... , May 22, 2013 ... drug-only formulation of glycopyrronium bromide designed using Prosonix, particle ... company developing a portfolio of inhaled Respiratory Medicines ... study with PSX1002 that will assess its effect on ... doses in patients with moderate to severe chronic obstructive ...
Breaking Biology Technology:Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4Bed Bugs Cost Alton Housing Authority $35,000; New Help, How to Kill Bed Bugs With Less Expense, Introduced by My Cleaning Products 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
... BNVI ), a leader in the discovery and development ... and cancer, is scheduled to,present at the Bank of Montreal,s ... Chesterman, SVP and CFO of Bionovo, Inc., will,take place on ... the,Millennium Broadway Hotel in New York City., To access ...
... 28 Carl Marks & Co. LP has partnered,with ... Life Sciences,Focus Fund LP. The partnership also gives Carl ... healthcare hedge funds, and an,increased presence in the healthcare ... highly concentrated portfolios which are,long and short public healthcare ...
... Nabi,Biopharmaceuticals (Nasdaq: NABI ) today announced that ... participate in the BMO,Capital Markets Focus on Healthcare Conference ... Hotel in New York, NY. Dr. Hudson,s,presentation at the ... ET., Dr. Hudson will present a company overview ...
Cached Biology Technology:Carl Marks Seeds New Healthcare Fund Through Strategic Partnership With BlueStar Capital Management 2Nabi Biopharmaceuticals to Present at the BMO Capital Markets Focus on Healthcare Conference 2
(Date:5/21/2013)... The concept of "place" is increasingly being considered ... now have a new resource that can help ... have with the places in their lives. ... a new book co-edited by the Pacific Northwest ... a human-centered approach to conservation. The book is ...
(Date:5/21/2013)... class of pharmaceuticals can both prevent and treat Alzheimer,s ... "TSPO ligands," are currently used for certain types of ... ligand in young adult mice when pathology was at ... was quite severe," said lead researcher Christian Pike of ... measures of pathology and improved behavior at both ages." ...
(Date:5/21/2013)... ANN ARBORThe new University of Michigan Water Center ... to support Great Lakes restoration and protection efforts. ... will support diverse projects, including efforts to track ... effectiveness of techniques to control non-native weedy plant ... and monitor fish responses to restoration activities. , ...
Breaking Biology News(10 mins):Drugs found to both prevent and treat Alzheimer's disease in mice 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4
... inches long, grows on wood, and is shaped like a ... , has been discovered on the African island of Sao ... Mycologia . The mushroom is named after Robert Drewes, ... is described in the July/August issue by Professor Dennis Desjardin ...
... PHILADELPHIA - Psychologists at the University of Pennsylvania ... "Unit Bias," which causes people to ignore vital, obvious ... flaw in the modern, evolved mind and may also ... of weight gain. Researchers who focus on the ...
... 15, 2009) A team of researchers led by Dr. ... biological marker for neovascular age-related macular degeneration (AMD), the leading ... a receptor known as CCR3, shows strong potential as a ... for preventive treatment. The findings were reported in an article ...
Cached Biology News:New species of phallus-shaped mushroom named after California Academy of Sciences scientist 2'Shortcuts' of the mind lead to miscalculations of weight and caloric intake, says Penn study 2'Shortcuts' of the mind lead to miscalculations of weight and caloric intake, says Penn study 3Major breakthrough in early detection and prevention of AMD 2Major breakthrough in early detection and prevention of AMD 3
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
TGF-beta 2 MAb (Clone 8607)...
Fluorescein-CSCSSLMDKECVYFCHLDIIW (Disulfide bridge: 1-15 and 3-11)...
... for isolation and affinity purification of ... peptides. Hydrophobic, monodisperse magnetic particles (2.8 ... groups, further surface activation is not ... with optimal orientation for affinity purification ...
Biology Products: